Overview

  • Product name

    Anti-RANK antibody [EPR4740(N)]
    See all RANK primary antibodies
  • Description

    Rabbit monoclonal [EPR4740(N)] to RANK
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human RANK aa 1-100 (N terminal). The exact sequence is proprietary.
    Database link: Q9Y6Q6

  • Positive control

    • Human fetal liver, fetal thymus and adult adrenal gland and small intestine tissue lysates.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab182158 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 80 kDa (predicted molecular weight: 66 kDa).

Target

  • Function

    Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Involved in the regulation of interactions between T-cells and dendritic cells.
  • Tissue specificity

    Ubiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland.
  • Involvement in disease

    Defects in TNFRSF11A are the cause of familial expansile osteolysis (FEO) [MIM:174810]. FEO is a rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early onset deafness and loss of dentition.
    Defects in TNFRSF11A are a cause of Paget disease of bone type 2 (PDB2) [MIM:602080]; also known as familial Paget disease of bone. PDB2 is a bone-remodeling disorder with clinical similarities to FEO. Unlike FEO, however, affected individuals have involvement of the axial skeleton with lesions in the spine, pelvis and skull.
    Defects in TNFRSF11A are the cause of osteopetrosis autosomal recessive type 7 (OPTB7) [MIM:612301]; also called osteoclast-poor osteopetrosis with hypogammaglobulinemia. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia.
  • Sequence similarities

    Contains 4 TNFR-Cys repeats.
  • Cellular localization

    Membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • CD 265 antibody
    • CD265 antibody
    • FEO antibody
    • LOH18CR1 antibody
    • Loss of heterozygosity 18 chromosomal region 1 antibody
    • mRANK antibody
    • ODFR antibody
    • OFE antibody
    • OPTB7 antibody
    • Osteoclast differentiation factor receptor antibody
    • OSTS antibody
    • Paget disease of bone 2 antibody
    • PDB 2 antibody
    • PDB2 antibody
    • RANK antibody
    • Receptor activator of NF KB antibody
    • Receptor activator of NF-KB antibody
    • receptor activator of nuclear factor kappa B antibody
    • TNF receptor superfamily member 11a antibody
    • TNFRSF11A antibody
    • TNR11_HUMAN antibody
    • TRANCER antibody
    • Tumor necrosis factor receptor superfamily member 11a NFKB activator antibody
    • Tumor necrosis factor receptor superfamily member 11a activator of NFKB antibody
    • Tumor necrosis factor receptor superfamily member 11A antibody
    see all

Images

  • All lanes : Anti-RANK antibody [EPR4740(N)] (ab182158) at 1/10000 dilution

    Lane 1 : Human adrenal gland tissue lysate
    Lane 2 : Human fetal liver tissue lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab136636) at 1/500 dilution

    Predicted band size: 66 kDa
    Observed band size: 80 kDa
    why is the actual band size different from the predicted?

  • All lanes : Anti-RANK antibody [EPR4740(N)] (ab182158) at 1/2000 dilution

    Lane 1 : Human small intestine tissue lysate
    Lane 2 : Human fetal thymus tissue lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab136636) at 1/500 dilution

    Predicted band size: 66 kDa
    Observed band size: 80 kDa why is the actual band size different from the predicted?

References

This product has been referenced in:

  • Fioramonti M  et al. Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. Sci Rep 8:4177 (2018). WB . Read more (PubMed: 29520051) »
  • Tohyama R  et al. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL. J Oral Pathol Med 45:356-64 (2016). WB ; Human . Read more (PubMed: 26859422) »
See all 2 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab182158.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up